Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 10
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Tandem Diabetes Care Inc
TNDM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$18.17
1.26
7.45%
Ult. Agg.: Nov 9, 7:59 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data gio nov 5th, dopo la chiusura del mercato
Conference call:
La conference call più recente è iniziata alle 4:30 PM, 4 giorni fa
Clicca per vedere il webcast
Tandem Diabetes Care Financials
Tandem Diabetes Care (TNDM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.072B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.072 billion estimate.
Benzinga Newsdesk
PRO
Tandem Diabetes Care Q3 EPS $(0.10) Beats $(0.25) Estimate, Sales $283.690M Beat $265.922M Estimate
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.25) by 60 percent. This is a 67.74 percent increase over losses of $(0.31) per share
Benzinga Newsdesk
PRO
Tandem Diabetes Care Q2 EPS $(0.31) Beats $(0.32) Estimate, Sales $254.560M Miss $254.978M Estimate
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.32) by 3.13 percent. This is a 60.26 percent increase over losses of $(0.78) per share
Benzinga Newsdesk
PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.074B Est
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.074 billion estimate.
Benzinga Newsdesk
PRO
Tandem Diabetes Care Affirms FY2026 Sales Guidance of $1.065B-$1.085B vs $1.076B Est.
Tandem Diabetes Care (NASDAQ:TNDM) affirms FY2026 sales outlook from $1.065 billion-$1.085 billion to $1.065 billion-$1.085 billion vs $1.076 billion estimate.
Benzinga Newsdesk
PRO
Tandem Diabetes Care Q1 Adj. EPS $(0.30) Beats $(0.45) Estimate, Sales $247.221M Beat $241.125M Estimate.
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.45) by 33.33 percent. This is a 54.55 percent increase over losses of $(0.67) per share
Benzinga Newsdesk
